ARIAD (ARIA) Buy Reiterated at Jefferies Following Doctor Survey
Tweet Send to a Friend
Jefferies reiterated a Buy rating and $25 price target on ARIAD Pharmaceuticals (NASDAQ: ARIA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE